Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche; Artur Bauhofer; Miguel Ãngel Gomez Bravo; Georges Philippe Pageaux; Fabien Zoulim; Alejandra Otero; Martin Prieto; Carmen Baliellas; Didier Samuel

doi:10.12659/AOT.936162

10 May 2022: Original Paper

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Bruno Roche ^1BCDE , Artur Bauhofer ^2ACDEF* , Miguel Ãngel Gomez Bravo ^3BCDE , Georges Philippe Pageaux ^4ABCDE , Fabien Zoulim ^5BDE , Alejandra Otero ^6BC , Martin Prieto ^78BC , Carmen Baliellas ^9BC , Didier Samuel ^1ACDE

DOI: 10.12659/AOT.936162

Ann Transplant 2022; 27:e936162

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 5 Frequencies of the 3 levels of perceived problems for each of the 5 dimensions of the EQ-5D at baseline (study start) and last FU. Percentages are based on the number of patients with data available for the respective dimension at the respective time point (shown in brackets) (Prepared with Microsoft Office 2016).

Back to the Article

Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study

Your Privacy